RenovoRx Inc
RNXT
View Detailed Chart
1.030USD
+0.010+0.98%
Close 11/05, 16:00（ET）Quotes delayed by 15 min
37.75MMarket Cap
LossP/E TTM
Intraday
1m
30m
1h
D
W
M
D
Today
+0.98%
5 Days
-1.90%
1 Month
-21.97%
6 Months
0.00%
Year to Date
-20.16%
1 Year
-0.96%
View Detailed Chart
TradingKey Stock Score of RenovoRx Inc
Currency: USD Updated: 2025-11-05Key Insights
The company's fundamentals are relatively very healthy. Its valuation is considered fairly valued,and institutional recognition is very high. Over the past 30 days, multiple analysts have rated the company as a Buy. Despite a weak stock market performance, the company shows strong fundamentals. The stock price is trading sideways between the support and resistance levels, making it suitable for range-bound swing trading.
RenovoRx Inc's Score
Support & Resistance
No Data
Score Analysis
Current score
Previous score
Analyst Rating
Based on
4
analysts
Buy
Current Rating
5.625
Target Price
+451.47%
Upside Space
Data disclaimer: Analyst ratings and target prices are provided by LSEG for informational purposes only and do not constitute investment advice.
RenovoRx Inc Highlights
StrengthsRisks
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.
Growing
The company is in a growing phase, with the latest annual income totaling USD 43.00K.
Undervalued
The company’s latest PE is -2.75, at a low 3-year percentile range.
Institutional Selling
The latest institutional holdings are 8.12M shares, decreasing 28.24% quarter-over-quarter.
Held by James Simons
Star Investor James Simons holds 251.80K shares of this stock.
Higher Market Activity
The company has more investor interest, with a 20-day turnover ratio of 0.57.
RenovoRx Inc News
More news coming soon, stay tuned...
Financial Indicators
EPS
No Data
Total revenue
No Data
RenovoRx Inc Info
RenovoRx, Inc. is a clinical-stage biopharmaceutical company. The Company is developing targeted combination therapies for high unmet medical needs with a goal of improving therapeutic outcomes for cancer patients undergoing treatment. Its Trans-Arterial Micro-Perfusion (TAMP) therapy platform is designed to ensure precise therapeutic delivery to directly target the tumor while potentially minimizing a therapy’s toxicities versus systemic intravenous therapy. Its portfolio of cancer therapies is based on its lead product candidate, RenovoGem (gemcitabine delivered via its delivery system). Its phase III lead product candidate, RenovoGem, is a novel oncology drug-device combination product. RenovoGem is being evaluated for the treatment of locally advanced pancreatic cancer (LAPC) by the Center for Drug Evaluation and Research. Its phase III registrational trial of RenovoGem for the treatment of LAPC is called TIGeR-PaC.
Ticker SymbolRNXT
CompanyRenovoRx Inc
CEOMr. Shaun R. Bagai
Websitehttps://renovorx.com/
Related Instruments
-0.93%
-1.00%
+0.42%
+1.81%
-0.76%
+0.06%
-1.36%
-0.02%
+0.32%
+0.60%
+0.46%
-1.92%
+2.75%
-0.26%
-1.48%
-1.56%
+0.60%
+0.47%
+0.20%
-0.48%Popular Symbols
